[¹¹C] choline as a potential PET/CT biomarker of liver cirrhosis: A prospective pilot study

Hemda Schmilovitz-Weiss, Doron Boltin, David Groshar, Liran Domachevsky, Eli Rosenbaum, Nidal Issa, Boris Sapoznikov, Idan Goren, Assaf Issachar, Michal Cohen-Naftaly, Avraham Weiss, Rachel Gingold-Belfer, Hanna Bernstine

Research output: Contribution to journalArticlepeer-review

Abstract

Aim of the study: To compare [¹¹C] choline PET/CT findings between patients with cirrhosis and normal liver controls. Methods: Included 11 patients with cirrhosis and 14 controls. All underwent a dynamic [11C] choline PET/CT. The maximal standard uptake values (SUVmax), the area under the curve (AUC) and kinetic parameters (K1 and K2), clinical and laboratory data, were compared between groups. Results: Patients mean age was 68.4 ± 10.7 and controls, 69.7 ± 7.3 years. Mean SUVmax was higher in patients than controls (right lobe, 10.06 ± 12 vs. 6.3 ± 1.6, P = 0.011; left lobe, 8.6 ± 11.6 vs. 5.4 ± 0.9, P = 0.024; spleen 17.99 ± 27.8 vs. 13.4 ± 2.6, P = 0.027; kidney, 35.9 ± 59.5 vs. 19.3 ± 4.8, P = 0.025) and also AUC values (right lobe, 13,538 ± 20,020 vs. 8427.3 ± 1557.9, P = 0.026; left lobe 12,304 ± 18,871 vs. 6878.9 ± 1294.3, P = 0.024; spleen, 12,875 ± 17,930 vs. 8263.9 ± 1279.2, P = 0.023; kidney, 24,623 ± 36,025 vs. 13,667 ± 3873.9, P = 0.032). No difference in kinetic parameters was found. No correlations between severity of clinical signs and imaging-derived parametric data were found among patients with cirrhosis. Conclusions: [11C] choline PET/CT may serve as a noninvasive biomarker for patients with cirrhosis.

Original languageEnglish
Pages (from-to)753-759
Number of pages7
JournalDigestive and Liver Disease
Volume53
Issue number6
DOIs
StatePublished - Jun 2021

Keywords

  • Biomarker
  • Cirrhosis
  • PET/CT
  • [¹¹C] choline

Fingerprint

Dive into the research topics of '[¹¹C] choline as a potential PET/CT biomarker of liver cirrhosis: A prospective pilot study'. Together they form a unique fingerprint.

Cite this